サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1551644

ウエストナイルウイルスの世界市場

West Nile Virus

出版日
ページ情報
英文 169 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
ウエストナイルウイルスの世界市場
出版日: 2024年09月10日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 169 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ウエストナイルウイルスの世界市場は2030年までに9億2,910万米ドルに達する見込み

2023年に6億1,590万米ドルと推定されるウエストナイルウイルスの世界市場は、2030年には9億2,910万米ドルに達し、分析期間2023-2030年のCAGRは6.0%で成長すると予測されます。本レポートで分析したセグメントの1つである抗ウイルス剤は、CAGR 7.2%を記録し、分析期間終了時には3億8,480万米ドルに達すると予測されます。抗生物質セグメントの成長率は、分析期間中CAGR 5.8%と推定されます。

米国市場は1億6,780万米ドルと推定、中国はCAGR9.9%で成長すると予測

米国のウエストナイルウイルス市場は、2023年に1億6,780万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年の分析期間においてCAGR 9.9%で推移し、2030年には予測市場規模2億70万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と6.1%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界のウエストナイルウイルス市場- 主要動向と促進要因まとめ

ウエストナイルウイルスとは何か、公衆衛生にどのような影響を与えるか？

ウエストナイルウイルス（WNV）は蚊を媒介とするウイルスで、世界中で公衆衛生上の重大な問題として浮上しています。1937年にウガンダで初めて確認されて以来、北米、欧州、アジアの一部を含む世界各地に広がっています。WNVは主に感染した蚊、特に多くの地域に生息するCulex属の蚊に刺されることでヒトに感染します。WNV感染症の大部分は無症状か、軽いインフルエンザのような症状であるが、このウイルスは、特に高齢者や免疫力が低下した人に、脳炎や髄膜炎などの重篤な神経疾患を引き起こす可能性があります。長期にわたる神経障害や死亡など、深刻な結果をもたらす可能性があることから、WNVは公衆衛生上の重要な問題となっています。世界の旅行や気候変動によって蚊の生息域が広がるにつれて、WNV発生のリスクは高まり続けており、サーベイランス、予防、治療の強化が必要となっています。

ウエストナイルウイルスの感染リスクが最も高いのは誰ですか？なぜそれほど危険なのでしょうか？

ウエストナイルウイルスは、高齢者、免疫不全者、糖尿病や高血圧などの持病を持つ人など、特定のハイリスク集団に特別な脅威をもたらします。これらの人々は、感染した場合、回復期間が長引いたり、後遺症が残る可能性のある神経学的合併症など、重篤な症状を発症する可能性が高いです。さらに、WNVが流行している地域の住民は、特に蚊が大量に発生する季節に、感染するリスクが高まる。WNVの危険性は、重篤な病気を引き起こす可能性だけでなく、多くの症例が無症状または非特異的な症状を呈するため、早期発見を逃れる能力にもあります。そのため診断や治療が遅れ、重症化する可能性が高くなります。公衆衛生当局は、WNVの影響を軽減するために、蚊の駆除プログラム、曝露を減らすための一般市民への教育、ワクチンや抗ウイルス治療薬の開発など、予防対策の重要性を強調しています。

ウエストナイルウイルス対策の最新動向とイノベーションとは？

ウエストナイルウイルスとの闘いは、検出、予防、治療戦略の改善に重点を置き、近年数多くの進歩を遂げています。最も重要な動向のひとつは、WNV感染を迅速に特定できる迅速診断検査の開発であり、これによりタイムリーな介入が可能になり、ウイルスの蔓延を抑えることができます。さらに、WNVに対する長期的な防御を可能にするワクチンの研究も進行中であり、これは、特にウイルスが頻繁に発生する地域において、ウイルスを制圧するための大きな突破口となると思われます。遺伝子組み換え蚊や環境にやさしい殺虫剤の使用など、蚊の駆除技術の進歩も、WNV保菌者の数を減らす上で重要な役割を果たしています。さらに、公衆衛生キャンペーンでは、デジタルプラットフォームを活用してWNV予防に関する情報を発信する機会が増えており、個人の防護対策や地域全体の蚊の駆除努力の重要性に対する認識を高めています。こうした技術革新は、WNVに対するより包括的で効果的な対応に寄与しているが、特に資源が限られた環境では、こうしたツールへのアクセスを広く確保することが課題として残されています。

ウエストナイルウイルス市場の主な成長促進要因は？

ウエストナイルウイルス市場の成長の原動力は、このウイルスがもたらす脅威の高まりを裏付けるいくつかの要因です。主な要因は、WNVを媒介する蚊の生息域を新たな地域に拡大しつつある世界の気候変動に後押しされた、WNV発生の増加です。この動向は、より効果的な監視、診断、予防対策への需要を促進しています。特に診断と蚊の駆除の分野における技術の進歩も、WNVの検出と蔓延を緩和するための、より効率的でスケーラブルなソリューションを提供することで市場の成長を後押ししています。WNVが重篤な神経疾患を引き起こす可能性があるという認識の高まりは、蚊の駆除対策や個人用防護製品などの予防対策の採用をさらに加速させています。さらに、ワクチンや抗ウイルス療法の開発が推進され、この公衆衛生の脅威と闘うために政府や保健機関が研究開発に投資することで、市場に新たな機会が生まれています。これらの要因は、継続的なモニタリングと管理努力の必要性と相まって、公衆衛生当局と民間団体がこのウイルスがもたらすリスクの高まりに対処しようとしているため、WNV市場の拡大を後押ししています。

調査対象企業の例（注目の25社）

  • CEL-SCI Corporation
  • Cipla Ltd.
  • Diagnostic Automation/Cortez Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc
  • Hawaii Biotech, Inc.
  • InBios International, Inc.
  • Johnson & Johnson Services, Inc.
  • Kineta, Inc.
  • Merck Animal Health
  • Novartis AG
  • Pfizer, Inc.
  • Response Biomedical Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Theravectys

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26789

Global West Nile Virus Market to Reach US$929.1 Million by 2030

The global market for West Nile Virus estimated at US$615.9 Million in the year 2023, is expected to reach US$929.1 Million by 2030, growing at a CAGR of 6.0% over the analysis period 2023-2030. Antivirals, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$384.8 Million by the end of the analysis period. Growth in the Antibiotics segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$167.8 Million While China is Forecast to Grow at 9.9% CAGR

The West Nile Virus market in the U.S. is estimated at US$167.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$200.7 Million by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global West Nile Virus Market - Key Trends and Drivers Summarized

What Is West Nile Virus and How Does It Impact Public Health?

West Nile Virus (WNV) is a mosquito-borne virus that has emerged as a significant public health concern across the globe. First identified in Uganda in 1937, the virus has since spread to various parts of the world, including North America, Europe, and parts of Asia. WNV is primarily transmitted to humans through the bite of infected mosquitoes, particularly the Culex species, which are common in many regions. While the majority of WNV infections are asymptomatic or result in mild flu-like symptoms, the virus can cause severe neurological diseases, such as encephalitis or meningitis, especially in older adults and individuals with weakened immune systems. The potential for severe outcomes, including long-term neurological damage or death, makes WNV a significant public health issue. As global travel and climate change contribute to the spread of mosquito habitats, the risk of WNV outbreaks continues to rise, necessitating increased surveillance, prevention, and treatment efforts.

Who Is Most at Risk from West Nile Virus and Why Is It So Dangerous?

West Nile Virus poses a particular threat to certain high-risk groups, including the elderly, immunocompromised individuals, and those with pre-existing health conditions such as diabetes or hypertension. These populations are more likely to develop severe symptoms if infected, including neurological complications that can lead to prolonged recovery periods or permanent disability. Additionally, residents of regions where WNV is endemic, particularly during peak mosquito season, face an increased risk of exposure. The danger of WNV lies not only in its potential to cause serious illness but also in its ability to evade early detection, as many cases are asymptomatic or present with nonspecific symptoms. This can delay diagnosis and treatment, increasing the likelihood of severe outcomes. Public health authorities emphasize the importance of preventive measures, such as mosquito control programs, public education on reducing exposure, and the development of vaccines and antiviral treatments to mitigate the impact of WNV.

What Are the Latest Trends and Innovations in Combating West Nile Virus?

The fight against West Nile Virus has seen numerous advancements in recent years, with a focus on improving detection, prevention, and treatment strategies. One of the most significant trends is the development of rapid diagnostic tests that can quickly identify WNV infections, enabling timely intervention and reducing the spread of the virus. Additionally, there is ongoing research into vaccines that could provide long-term protection against WNV, which would be a major breakthrough in controlling the virus, particularly in regions with frequent outbreaks. Advances in mosquito control technologies, such as the use of genetically modified mosquitoes and environmentally friendly insecticides, are also playing a critical role in reducing the population of WNV carriers. Furthermore, public health campaigns are increasingly leveraging digital platforms to disseminate information about WNV prevention, raising awareness about the importance of personal protective measures and community-wide mosquito control efforts. These innovations are contributing to a more comprehensive and effective response to WNV, though challenges remain in ensuring widespread access to these tools, particularly in resource-limited settings.

What Are the Key Growth Drivers for the West Nile Virus Market?

The growth in the West Nile Virus market is driven by several factors that underscore the escalating threat posed by this virus. A key driver is the increasing incidence of WNV outbreaks, fueled by global climate change, which is expanding the habitats of WNV-carrying mosquitoes into new regions. This trend is driving demand for more effective surveillance, diagnostic, and preventive measures. Technological advancements, particularly in the fields of diagnostics and mosquito control, are also propelling market growth by offering more efficient and scalable solutions for detecting and mitigating the spread of WNV. The growing awareness of WNV's potential to cause severe neurological disease is further accelerating the adoption of preventive measures, including mosquito control initiatives and personal protective products. Additionally, the push for the development of vaccines and antiviral therapies is creating new opportunities within the market, as governments and health organizations invest in research and development to combat this public health threat. These factors, coupled with the need for ongoing monitoring and control efforts, are driving the expansion of the WNV market as public health authorities and private sector entities seek to address the rising risk posed by this virus.

Select Competitors (Total 25 Featured) -

  • CEL-SCI Corporation
  • Cipla Ltd.
  • Diagnostic Automation / Cortez Diagnostics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc
  • Hawaii Biotech, Inc.
  • InBios International, Inc.
  • Johnson & Johnson Services, Inc.
  • Kineta, Inc.
  • Merck Animal Health
  • Novartis AG
  • Pfizer, Inc.
  • Response Biomedical Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Theravectys

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • West Nile Virus - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Mosquito-Borne Diseases Propels Focus on West Nile Virus Market
    • Climate Change Throws the Spotlight on Expanding Mosquito Habitats and Disease Spread
    • Advancements in Diagnostic Technologies Strengthen Business Case for West Nile Virus Detection
    • Government and Public Health Initiatives Accelerate Demand for West Nile Virus Surveillance
    • Increased Awareness of Long-Term Neurological Effects Drives Research and Vaccine Development
    • Expanding Vector Control Programs Generate Demand for Integrated Mosquito Management Solutions
    • Innovation in Antiviral Therapies Propels Growth in West Nile Virus Treatment Options
    • Focus on Rapid Response and Preparedness Drives Adoption of New Surveillance Technologies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World West Nile Virus Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for West Nile Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for West Nile Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for West Nile Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antivirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • CHINA
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for West Nile Virus by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for West Nile Virus by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for West Nile Virus by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for West Nile Virus by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for West Nile Virus by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for West Nile Virus by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • INDIA
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for West Nile Virus by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for West Nile Virus by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for West Nile Virus by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for West Nile Virus by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for West Nile Virus by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for West Nile Virus by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030
  • AFRICA
    • West Nile Virus Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for West Nile Virus by Drug Class - Antivirals, Antibiotics, Analgesics and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for West Nile Virus by Drug Class - Percentage Breakdown of Value Sales for Antivirals, Antibiotics, Analgesics and Other Drug Classes for the Years 2014, 2024 & 2030

IV. COMPETITION